GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HilleVax Inc (NAS:HLVX) » Definitions » Earnings per Share (Diluted)
中文

HilleVax (HilleVax) Earnings per Share (Diluted) : $-3.04 (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is HilleVax Earnings per Share (Diluted)?

HilleVax's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.78. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.04.

HilleVax's EPS (Basic) for the three months ended in Dec. 2023 was $-0.78. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.04.

HilleVax's EPS without NRI for the three months ended in Dec. 2023 was $-0.78. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.04.

During the past 3 years, the average EPS without NRIGrowth Rate was -186.70% per year.

During the past 4 years, HilleVax's highest 3-Year average EPS without NRI Growth Rate was -186.70% per year. The lowest was -186.70% per year. And the median was -186.70% per year.


HilleVax Earnings per Share (Diluted) Historical Data

The historical data trend for HilleVax's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HilleVax Earnings per Share (Diluted) Chart

HilleVax Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
-0.13 -6.29 -5.89 -3.04

HilleVax Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.56 -0.71 -0.74 -0.81 -0.78

Competitive Comparison of HilleVax's Earnings per Share (Diluted)

For the Biotechnology subindustry, HilleVax's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HilleVax's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HilleVax's PE Ratio distribution charts can be found below:

* The bar in red indicates where HilleVax's PE Ratio falls into.



HilleVax Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

HilleVax's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-123.566-0)/40.598
=-3.04

HilleVax's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-36.96-0)/47.635
=-0.78

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


HilleVax  (NAS:HLVX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


HilleVax Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of HilleVax's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


HilleVax (HilleVax) Business Description

Industry
Traded in Other Exchanges
N/A
Address
75 State Street, Suite 100 - No. 9995, Boston, MA, USA, 02109
HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Executives
Astrid Borkowski officer: Chief Medical Officer C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Nanette Cocero director C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109
Shane Maltbie officer: Chief Financial Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Frazier Life Sciences X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Fhmls X, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Gary Dubin director C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Jaime Sepulveda director C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109
Takeda Vaccines, Inc. 10 percent owner 75 SIDNEY STREET, CAMBRIDGE MA 02139
Shelley Chu director ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Fhmls X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Julie L. Gerberding director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aditya Kohli director, officer: Chief Operating Officer C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
David A Socks officer: CFO & Chief Business Officer C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668